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Abstract
While stable mixed-hematopoietic chimerism induces robust immune tolerance to solid organ 
allografts in mice, the translation of this strategy to large animal models and to patients has been 
challenging. We have previously shown that in MHC-matched NHP, a busulfan plus combined 
belatacept and anti-CD154 -based regimen could induce long-lived myeloid chimerism, but 
without T cell chimerism. In that setting, donor chimerism was eventually rejected and tolerance 
to skin allografts was not achieved. Here we describe an adaptation of this strategy, with the 
addition of low-dose total body irradiation (TBI) to our conditioning regimen. This strategy has 
successfully induced multilineage hematopoietic chimerism in MHC-matched transplants that was 
stable for as long as 24 months post-transplant, the entire length of analysis. High-level T cell 
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chimerism was achieved and associated with significant donor-specific prolongation of skin graft 
acceptance. However, we also observed significant infectious toxicities, prominently including 
CMV reactivation and end-organ disease in the setting of functional defects in anti-CMV T cell 
immunity. These results underscore the significant benefits that multilineage chimerism-induction 
approaches may represent to transplant patients as well as the inherent risks, and emphasize the 
precision with which a clinically successful regimen will need to be formulated and then validated 
in NHP models.
Introduction
One of the prevailing hypotheses in the field of solid organ transplantation is that if stable 
mixed chimerism could be reproducibly induced, then immune tolerance to both skin and 
solid organ allografts from the same donor would follow. In murine models, this strategy has 
met with widespread success.(1–15) The critical importance of attaining and maintaining 
multilineage chimerism for tolerance-induction has also been demonstrated in mice, where it 
has been shown that in the absence of T cell chimerism, tolerance-induction could not be 
achieved. (16, 17) The significance of T cell chimerism to multilineage donor allogeneic 
hematopoietic cell chimerism stability has also been observed in clinical transplantation, 
where patients that lack substantial (>50–75%) donor T cell engraftment even in the setting 
of significant myeloid chimerism, are at high risk for loss of the donor hematopoietic graft.
(18–21) While the mechanisms controlling T cell chimerism-mediated tolerance are not 
completely understood, they likely include the migration of both donor T cells and T cell 
precursors to the thymus to promote central tolerance.(16, 17, 22)
While chimerism-based strategies for tolerance-induction have achieved widespread success 
in mice, the translation of the intentional induction of stable multilineage mixed-chimerism 
to NHP models and to the clinic has been more challenging. This is especially the case after 
lower intensity non-myeloablative pre-transplant conditioning, with most work focused on 
inducing transient chimerism (17, 23–27). Alternatively, others have chosen to significantly 
escalate the intensity of pre-transplant conditioning to establish the donor graft (28–31) or to 
induce full-donor rather than mixed chimerism. (32–34) Our group has built on our 
experience with reduced-intensity pre-transplant conditioning and T cell costimulation-
blockade-mediated chimerism- and tolerance-induction in mice (1–3, 5, 6) as the platform 
for translation to NHP. Using an MHC-defined NHP model, we first sought to determine if 
we could directly translate the success in mice, using a busulfan-based conditioning regimen 
and either anti-CD154 or anti-CD40 antibodies plus CD80/86-directed costimulation 
blockade-based immunomodulation to NHP. Our previous work demonstrated the successful 
induction of long-lived (> 1 year) myeloid-predominant chimerism with this regimen.(1, 35–
38) However, unlike in mice, reduced-intensity busulfan-only conditioning in NHP did not 
lead to significant T cell chimerism (35, 36) and without significant T cell chimerism, the 
donor hematopoietic graft was eventually rejected by host T cells (35, 36, 39) (at a pace 
directly related to the degree of MHC disparity).(36) This transient chimerism did not 
induce tolerance to renal allografts.(38) Here we report an adapted transplant strategy that 
can lead to long-lived multilineage mixed chimerism, and in the setting of significant T cell 
chimerism, is associated with tolerance to donor hematopoiesis and prolonged skin graft 
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acceptance. Importantly, however, these transplants also provide an important cautionary 
tale: this tolerance-induction regimen was associated with a significant risk of infectious 
disease complications (prominently including CMV reactivation and disease), along with 
evidence for functional deficits in anti-viral protective immunity. Further refinements of this 
transplant strategy designed to ‘thread the needle’ of allograft tolerance while maintaining 
intact protective immunity, are needed for successful translation to the clinic.
Materials and Methods
Experimental animals
This study used Indian-origin rhesus macaques (18 animals) from the Yerkes National 
Primate Research Center, the Washington National Primate Research Center and the NIH-
sponsored rhesus macaque colony operated by Alphagenesis Inc. The study was conducted 
in strict accordance with USDA regulations and the recommendations in the Guide for the 
Care and Use of Laboratory Animals. It was approved by both the Emory University, and the 
University of Washington Institutional Animal Care and Use Committees.
MHC Typing
Details of the MHC typing and disparity between donors and recipients are described in 
detail in Supplementary Methods.
Transplant preparation and immunosuppression strategy
The transplant strategy is shown in Figure 1, and is based on our previously published 
costimulation-blockade-based immunosuppression strategy (35, 36), with the addition of 
low-dose (200 or 300 cGray; cGy) total body irradiation (TBI, delivered with a linear 
accelerator (Varian) at a dose-rate of </=7cGy/min) to the busulfan-based pre-transplant 
conditioning regimen. Details of the strategy and dosing regimens are described in 
Supplementary Methods.
Hematopoietic stem cell transplant (HCT) protocol
HCT utilized leukopheresis-derived hematopoietic stem cells (HSC), harvested using a 
COBE Spectra or Spectra Optia apparatus from donors that underwent GCSF-based 
mobilization (50mcg/kg x 5 days SQ) as previously described (35, 36). The total nucleated 
cell dose/kg, total CD3+ T cell dose/kg and total CD34+ cell dose/kg for each transplant 
recipient is shown in Table 1.
Chimerism determination
Bone marrow, whole blood and flow-cytometry-sorted myeloid cells (CD3−/CD20−/
CD14+), T cells (CD3+/CD20−/CD14−) and B cells (CD3−/CD20+/CD14−) were analyzed 
for donor chimerism based on divergent microsatellite markers at the UC Davis veterinary 
genetics laboratory as previously described.(35, 36)
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CMV monitoring, Primary Prophylaxis and Treatment
Cytomegalovirus (CMV) monitoring, primary prophylaxis and treatment are described in 
Supplementary Methods.
ELISPot Analysis of CMV-specific T cell Immunity
ELISPot analysis was performed as previously described and detailed in Supplementary 
Methods.
Longitudinal flow cytometric analysis of T cell phenotype
Immune cell subpopulations were quantified flow cytometrically as previously described 
(details supplied in Supplementary Methods).
Skin allografting
Details of skin allografting are supplied in the Supplementary Methods.
Statistical analysis
Anova and Kaplan-Meier analysis was carried out using GraphPad Software Version 6. To 
determine Anova for multiple parameters, a post-hoc Tukey HST test was used to determine 
significant differences for pair-wise comparisons.
Results
Multilineage mixed chimerism in NHP
In this study we designed a stringent multi-year transplant protocol using MHC-matched 
transplant pairs, in which our previously published busulfan/costimulation blockade/
sirolimus-based regimen(35, 36) was modified in order to enhance donor lymphoid 
chimerism (40) with low-dose (200–300 cGy) TBI.(41–43) As shown in Figure 1, 
completion of the entire experimental protocol required at least 25 months of follow-up: 
This included a pre-transplant conditioning phase (2 weeks) and on-therapy phase (10 
months) during which recipients were first conditioned with non-myeloablative doses of 
busulfan + TBI, and then treated with sirolimus/5C8/belatacept, followed by sequential 
discontinuation in the following order: sirolimus→5C8→belatacept. After all 
immunosuppression was weaned, recipients were monitored for at least 12 months for 
chimerism stability, followed by skin allografting. As shown in Figure 2A,B, this 
conditioning regimen in conjunction with costimulation blockade/sirolimus-based post-
transplant immunosuppression, was successful in creating multilineage chimerism in all 
transplant recipients. However, only 3 of the 9 transplanted animals completed the entire 
transplant protocol; the remaining animals reached protocol endpoint criteria due to clinical 
evidence of disease not responsive to treatment (on Days 32–202 post-transplant), each with 
infectious toxicities (discussed in detail below). For two of the three surviving animals, R.51 
and R.52, multilineage mixed chimerism was sustained for the entire experiment. For the 
third transplant recipient, R.53, who received a sub-standard dose of donor cells after a 
problematic apheresis procedure [including a ~10-fold lower dose of total nucleated cells 
(TNC) CD34+ and CD3+ cells, Table 1], the initial chimerism set-point was substantially 
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lower compared to the other recipients (27% BM chimerism at Day +30 compared to 88% +/
− 8.8% in the remaining 8 animals, Figure 2A). As shown in Figure 2B, R.53 lost chimerism 
at Day 383 post-transplant.
High incidence of CMV reactivation and other infectious disease complications amidst 
defects in anti-viral T cell function
While the creation of multilineage mixed chimerism that was capable of lasting more than 
2–3 years (Figure 2B) is a striking result, one of the most important observations made in 
this study was the high incidence of infections that occurred. As shown in Table 1 and 
Figure 3, transplant recipients all experienced serious infectious disease complications. 
These prominently included CMV reactivation and disease (despite the fact that all 
recipients received primary prophylaxis and secondary CMV treatment using a regimen that 
has successfully prevented high-level CMV reactivation and disease in our other NHP 
studies) (36) but also included bacterial complications, including Giardia enterocolitis, 
Bacillus bacteremia, and multi-drug resistant E. coli bacteremia. To quantify the impact of 
the transplant regimen on T-cell mediated anti-CMV immunity, we used ELISPot assays 
directed at CMV antigens in eight animals for which we had available samples. These 
included two transplant recipients who survived long-term (R.51 and R.53) and two 
recipients who died early in the setting of CMV reactivation (R.55) and with CMV disease 
(R.58) (Figure 4). For each transplant, we assayed T cell responses pre-transplant for both 
the recipient and the donor, and at the time of necropsy in the transplant recipient. These 
results showed significant functional deficits of anti-CMV immunity in R.55 and R.58 at the 
time of necropsy. In contrast to the results with R.55 and R.58, at the time of necropsy, two 
of the long-term survivors (R.51 and R.53) had greater CMV-specific responses when 
compared to their responses at pre-transplant. It is important to note that the necropsy 
samples for the sick animals (R.55 and R.58) were obtained when they were still on 
immunosuppression, while the necropsy samples from R.51 and R.53 were obtained after 
immunosuppression withdrawal but with ongoing mixed chimerism.
Impact of sirolimus and costimulation blockade on hematologic reconstitution after 
transplantation
To investigate the hematologic associations with transplant course, a detailed longitudinal 
investigation of immune reconstitution was performed. Figure 5 shows the White Blood Cell 
Count (WBC), Absolute Neutrophil Count (ANC) and Absolute Lymphocyte Count (ALC) 
for all recipients. These data demonstrate that generalized lymphopenia developed and 
persisted in the setting of triple immunosuppression with sirolimus/5C8/belatacept. While 
the high risk of infectious complications led to early experimental termination in 6 
recipients, as noted above, three animals (R.51, R.52 and R.53) were evaluable for the entire 
25-month experiment. In each of these recipients, lymphopenia persisted after sirolimus 
withdrawal (during continued costimulation blockade with 5C8 and belatacept), and 
continued until discontinuation of 5C8, at which time there was a significant increase in 
lymphocyte counts, despite ongoing treatment with belatacept. There were no further 
increases in total lymphocyte counts when belatacept was discontinued.
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Figure 6 shows a detailed analysis of the impact of immunosuppression withdrawal on B and 
T cells in R.51. As shown in this Figure, as with the total lymphocyte counts (Figure 5), the 
post-transplant expansion of the T cell compartment was significantly suppressed during 
triple-agent immunomodulation. Control of T cell expansion persisted despite the 
discontinuation of sirolimus, (in the setting of combined costimulation blockade with 5C8 
and belatacept). In contrast, the withdrawal of 5C8 (with continued treatment with 
belatacept) resulted in both CD4+ and CD8+ T cell counts significantly rebounding, with no 
further increase after the discontinuation of belatacept (Figure 6A). The withdrawal of 
sirolimus and 5C8 also resulted in a significant shift in the T cell subset balance, with a shift 
in the proportion of both CD4 and CD8 T cell subsets away from the CD28+/CD95− naïve 
phenotype (Figure 6B). In CD4+T cells this was accompanied by both a proportional and 
absolute expansion of CD28+/CD95+ central memory T cells (Tcm). In CD8+ T cells, the 
loss of the Tnaive phenotype was accompanied by a significant shift towards both CD28+/
CD95+ Tcm and CD28−/CD95+ effector memory (Tem) phenotype, with Tcm > Tem 
expansion. As shown in Figure 6 A,B, discontinuation of belatacept, and thus, the total 
withdrawal of all maintenance immunosuppression, resulted in no further shift in 
subpopulation balance or further expansion of conventional T cell numbers. Analysis of Treg 
homeostasis demonstrated a different pattern, with a proportional drop in these cells after 
withdrawal of sirolimus and 5C8, which did not recover until withdrawal of belatacept 
(Figure 6C). Moreover, the absolute number of Tregs did not significantly expand until after 
triple immunosuppression withdrawal.
Development of graft-versus-host disease (GVHD) in R.52
While none of the other animals in this study developed clinically apparent graft-versus-host 
disease, on Day 255 post-transplant, animal R.52 developed a skin rash covering 60% of his 
body surface area (BSA), that, when biopsied, showed histologic evidence of GVHD. This 
animal had previously experienced an episode of vomiting for which GVHD was considered 
in the differential diagnosis but developed neither diarrhea nor hyperbilirubinemia post-
transplant. The diagnosis of GVHD prompted us to treat this recipient with oral prednisone 
from Day 271 to Day 550 post-transplant (with weaning and full discontinuation of 
prednisone prior to skin graft placement). Of note, T cell chimerism was stable prior to, 
during, and after the development and treatment of R.52 for GVHD (see Figure 2B).
Prolongation of Donor Skin Graft Acceptance in Transplant Recipients with Significant T 
Cell Chimerism
The survival of R.51, R.52 and R.53 to the 2+ year experimental endpoint allowed us to test 
the impact of T cell chimerism on skin graft survival. We had tested this on a previously 
reported animal (‘RQq9, conditioned with Busulfan alone, without concomitant TBI), who 
had developed very low T cell chimerism, and who had demonstrated donor skin graft 
rejection that occurred within 30 days.(36) As shown in Figure 7, in the current study, we 
observed a direct relationship between the percent T cell chimerism and the length of skin 
allograft survival. Thus, as shown in Figure 7A, R.51, who demonstrated stable, high-level T 
cell chimerism (~70% at the time of skin-graft placement), demonstrated long-term 
acceptance of both autologous and donor skin (>100 days) despite rapid rejection of 
unrelated, third-party skin (rejection by 9 days post-skin graft placement, Figure 7A). R.51 
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is thus the first NHP in our experience to meet the formal definition of long-term stable 
multilineage mixed-chimerism and donor-specific tolerance, having maintained mixed 
donor-recipient hematopoiesis for over 700 days, and donor-specific acceptance of skin 
allografts for over 100 days. R.52, who demonstrated significant levels of T cell chimerism, 
but which were lower than in R.51, also demonstrated significant prolongation of donor skin 
graft acceptance. In this recipient, third-party skin was rejected promptly (9 days) while 
donor skin was accepted for significantly longer (~69 days, Figure 7B). Importantly, 
however, R.52 eventually rejected the donor skin while autologous skin was accepted long 
term. It should be noted, as discussed above, that R.52 was also the animal who developed 
skin GVHD. Recipient R.53, who lost donor chimerism prior to skin graft placement, 
showed rejection of the donor skin graft at a similar tempo to previous recipients who had 
never developed T cell chimerism, showing signs of rejection by Day 40 post-skin graft 
placement (Figure 7C). This observation is important, as it provides evidence to support the 
hypothesis that significant T cell chimerism, rather than the conditioning regimen (which 
was identical in R.51, R.52 and R.53), was associated with skin graft tolerance. Of note, a 
fourth recipient, RDe9, who had been previously reported as the one recipient with stable 
chimerism in an earlier experimental cohort not-receiving TBI,(36) (for whom the donor was 
unfortunately not available for skin grafting), has now been followed for more than 10 years 
post-transplant, and has been a stable multi-lineage mixed chimera for the entire follow-up 
period, in the setting of substantial T cell chimerism (currently at 30%, with follow up for 
>10 years, Figure 2D). Taken together, these results are consistent with the acquisition of T 
cell chimerism as highly associated with long-term allograft acceptance, including both 
acceptance of bone marrow and skin graft tolerance. Indeed, although the numbers of 
recipients analyzed was small, three important observations arise from the skin allograft 
experiments, shown in Figure 7. First, we found that it was possible to create a scenario (R.
51) in which tolerance to both bone marrow and skin was created. Second, in the 4 animals 
on whom skin grafts were placed (three in the current study, one in a previous study(36), 
there was a direct correlation between the percent T cell chimerism and donor allograft 
survival (Figure 7D). Finally, in each of these animals, immune competence to allografts 
were maintained, given the rapid rejection of third party skin in 3/3 animals tested.
Discussion
In this study, we demonstrate that a transplant strategy employing a non-myeloablative 
busulfan/TBI conditioning regimen and costimulation blockade +sirolimus-based 
immunomodulation can reliably produce multilineage mixed chimerism, and in the setting 
of substantial and stable T cell chimerism, donor-specific acceptance of a skin allograft is 
achievable. These results are notable, given the demonstration that stable multilineage mixed 
chimerism can be intentionally created in primates. This represents, to our knowledge, the 
longest duration of stable multilineage mixed chimerism-induction in NHP. As such, these 
data provide proof-of-concept that, even in outbred primates, stable T cell mixed-chimerism 
can be achieved by design. As we will discuss in detail below, the results of this study also 
underscore the significant risks of infectious disease complications that can accompany this 
transplant regimen, indicating that further modifications are necessary before translation to 
the clinic.
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This study is distinguished from others in the field by two facts: (1) That it sought to 
intentionally create mixed donor/recipient T cell chimerism and (2) That it sought to create 
multilineage mixed chimerism that was stable post-transplant. Thus, the group at 
Massachusetts General Hospital (MGH) has developed a transplant regimen in NHP that 
leads to transient donor chimerism, with rejection of the donor BMT within one month of 
transplantation. (23–27) In NHP, this regimen is effective in achieving long-term renal 
allograft tolerance in ~half of the renal transplant recipients. Encouragingly, clinical trials of 
BMT plus renal transplant based on these NHP studies resulted in multiple patients being 
weaned off of immunosuppression. (28, 29, 44–46) However, a significant engraftment 
syndrome(44) developed in several patients, suggesting that loss of the donor hematopoietic 
graft may have untoward effects in humans that were not observed in NHP. An independent 
clinical transplant series from the Stanford group has led to sustained donor chimerism in 
the setting of intensive total lymphoid irradiation (TLI, 1200cGy) plus ATG during 
combined BMT plus renal transplant. This regimen has been successful in achieving stable 
mixed chimerism and tolerance to the renal allograft in a number of MHC-matched donor/
recipient pairs. (28–31). Whether this regimen will be translatable to the more commonly 
encountered MHC-mismatched setting is not yet known. Finally, the Leventhal and Ildstadt 
group has reported full donor engraftment (ie not mixed chimerism, but rather full 
replacement with donor hematopoieisis) and long-term allograft acceptance in patients given 
combined hematopoietic and renal transplants in the presence of facilitating cells. While this 
trial is not a ‘mixed-chimerism’ trial per se, if long-term GVHD-free immunosuppression-
free survival becomes a reality for these patients, it is of high significance to the field.
In the current study, by closely monitoring the impact of sequential withdrawal of sirolimus, 
followed by anti-CD154 followed by belatacept, we gained important insights into the 
impact of triple, dual and single immunomodulation on T cell reconstitution and 
subpopulation balance. Our results demonstrate a significant suppression of absolute T cell 
counts and preservation of naïve T cell predominance during sirolimus and dual 
costimulation blockade. The suppression of T cell expansion and changes in T cell 
subpopulation balance was maintained despite discontinuation of sirolimus. When anti-
CD154 treatment was also discontinued (during monotherapy treatment with belatacept), we 
observed both T cell expansion and a shift in the subpopulation balance, from a Tnaive 
predominance to a Tcm predominance for both CD4 and CD8 T cells (with CD8 T cells also 
expanding the Tem compartment). Importantly, while no further quantitative or qualitative 
changes occurred in the conventional T cell compartment after withdrawal of belatacept, 
discontinuation of this therapy was associated with expansion of Tregs. The shift in CD8+ T 
cells to a Tcm (rather than Tem)-predominance is a new finding that we have not observed 
with our previous mixed-chimerism experiments.(35–38) While this, along with the eventual 
expansion of Tregs is notable, it is not clear if these shifts represent causation or correlation 
with tolerance-induction. As such, this represents an important area for future study. 
Importantly, these data also indicate that reciprocal tolerance to both donor and recipient 
hematopoiesis could persist despite both the T cell expansion and the shift in the naïve/
memory T cell balance that occurred after immunosuppression withdrawal, indicating robust 
control of both host-versus-graft and graft-versus-host vectors of T cell activation towards 
hematopoiesis with this transplant strategy.
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The stability of bidirectional tolerance to hematopoiesis (permitting the coexistence of both 
donor and recipient T cells) also suggests that central tolerance mechanisms contributed to 
long-term acceptance of the hematopoietic graft in this model. The observation of donor 
chimerism in 3 of 4 isolated thymi is supportive of this hypothesis (Figure 2C). The 
significant duration of triple→double→single agent immunomodulation (with some form of 
immunosuppression present for 300 days post- transplant) may have facilitated the 
development of central tolerance, by providing sufficient immunosuppression-mediated 
immune restraint to permit trafficking of donor cells to the thymus.
One of the other central experiments performed in this transplant series was the placement of 
autologous, donor, and non-donor ‘third-party’ skin allografts a full year after withdrawal of 
sirolimus and costimulation blockade. This experiment demonstrated long-term acceptance 
(>100 days) in the recipient with the highest level of T cell chimerism, prolonged but limited 
skin graft acceptance in a recipient with lower, but still significant T cell tolerance, and 
prompt rejection of donor skin in two recipients with no T cell chimerism. These data 
suggest that as in mice, in primates, tolerance to tissues may require significant, stable T cell 
chimerism. One important caveat to the current studies is the well-recognized “high bar” for 
tolerance induction that skin grafts represent. It is possible that less immunogenic grafts, 
such as renal or liver allografts, could have a lower threshold for T cell chimerism required 
for tolerance-induction. Indeed, we also observed GVHD of the skin in R.52, which, while 
reversible with steroids, suggests that the difficulty in attaining tolerance to skin antigens 
occurred in both the host-versus-graft and graft-versus-host direction in this animal. Renal 
allograft studies (both proof-of-concept delayed renal transplantation as well as renal 
allografts placed concurrently with chimerism-induction) thus represent an important area 
for future research, once an optimized regimen, able to support stable mixed chimerism 
while minimizing infectious complications, is developed.
Despite the success in creating donor chimerism that was capable of lasting for several 
years, the extremely high rate of loss of our transplant recipients due to infectious disease 
complications represents a sobering reality. In the current study, 8/9 recipients experienced 
CMV reactivation, despite all recipients receiving primary prophylaxis with cidofovir. In 2 
of these recipients, CMV end-organ disease was associated with recipient death, 
underscoring the seriousness of CMV disease in this transplant regimen, and the difficulty of 
reversing CMV disease in NHP, a phenomenon that has been documented previously by our 
group and others.(35, 36, 47–52) Whether the clinical challenges encountered with this virus 
is an inherent attribute of the NHP-specific CMV virus, or due to decreased efficacy of 
standard antivirals against rhesus CMV is not known. Delivering effective treatment for 
CMV is also considerably more challenging in NHP than patients, which could also have 
negatively affected our ability to control reactivated virus. Importantly, the most significant 
infectious disease complications occurred during the period of active immunosuppression, 
rather than during the period of sustained mixed chimerism, with R.52 and R.53 being much 
more stable from an infectious disease standpoint after immunosuppression withdrawal than 
they were on triple, double or single-agent therapy. This observation suggests that a rigorous 
step-wise elimination experiment is warranted, to determine which elements of the 
conditioning regimen and immunomodulatory strategy are required for stable multilineage 
mixed chimerism, and which produce the most severe functional defects in protective 
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immunity. If successful, this approach may yield a regimen that can succeed in producing 
tolerance without the defects in protective immunity observed in this transplant series. While 
it is not yet clear which of the elements of pre-transplant conditioning or post-transplant 
immunomodulation are the most important to eliminate/alter, our results suggest that a 
regimen that drives less severe lymphopenia while maintaining a positive Treg:Tcon balance 
would potentially tip the balance in favor of specific tolerance to the donor with less global 
defects in anti-viral protective immunity.
In summary, this transplant series has demonstrated a series of important milestones, as well 
as challenges to tolerance induction. We describe a transplant regimen that is consistently 
able to induce multilineage mixed chimerism as well as proof-of-concept that in the setting 
of significant T cell mixed chimerism, donor-specific tolerance, even to a highly 
immunogenic skin graft, is possible. We also demonstrate an important pitfall with this 
regimen, encapsulated by the significant clinical risks of infectious disease-related morbidity 
and mortality that these transplant recipients faced. These risks provide strong rationale for 
further iteration of this tolerance induction strategy to identify the minimally-effective 
immunomodulation strategy. Standing at the precipice of intentional multilineage mixed-
chimerism and tolerance-induction, these studies underscore both the significant benefits 
that these approaches may represent to patients as well as the risks, and emphasize the 
precision with which clinically successful regimens will need to be formulated.
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Figure 1. Transplant and Immunosuppression Strategy
Transplant strategy with details of conditioning regimen, doses of immunosuppression given 
and immunosuppression discontinuation end points. Busulfan was given on day −1 at a dose 
of 9.5mg/kg. The hematopoietic stem cell transplant took place on day 0. The 
immunosuppressive regimen was given as shown by the arrows in the figure, with each 
arrow representing an individual dose of drug, at the following concentrations: Belatacept 
(20mg/kg), Basiliximab (0.3mg/kg), Anti-CD154 (20mg/kg), sirolimus (once daily dosing 
was begun at 0.025mg/kg and adjusted to achieve a serum trough level of 10–15mg/mL). 
Autologous and donor skin grafts were placed as shown. Third party grafts were placed 
approximately 150 days after the placement of the donor and autologous skin grafts.
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Figure 2. Multilineage mixed chimerism-induction after nonmyeloablative HSCT in MHC-
matched transplant pairs
(A) Whole blood, bone marrow, T cell, B cell, and granulocyte chimerism of recipient 
animals at day 30 post-transplant shown as individual points. R.53 is shown as a red point, 
all other recipients shown as black points. Mean and standard deviation are shown as blue 
boxes and whiskers.
(B) Longitudinal analysis of whole blood chimerism, bone marrow chimerism, T cell 
chimerism, B cell chimerism, and granulocyte chimerism for all transplant recipients. Color-
coded bars below each graph indicate duration of immunosuppression (black bar: Sirolimus, 
“Sir”; red bar: anti-CD154, “5C8”; blue bar: Belatacept, “Bela”).
(C) Thymic chimerism at time of necropsy for 4 recipients for which thymic tissue was 
obtainable at necropsy (R.51, R.54, R.55, R59). Individual chimerism values shown as black 
points. Mean and standard deviation are shown as blue boxes and whiskers.
(D) Long-term follow up of whole blood chimerism, bone marrow chimerism, T cell 
chimerism, B cell chimerism, and granulocyte chimerism for a previously reported (36) 
recipient (‘RDe9’) with stable multilineage mixed-chimerism.
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Figure 3. Longitudinal Analysis of CMV Viral Load
CMV viral load is shown for all transplanted animals. Color-coded bars below each graph 
indicate duration of immunosuppression (black bar: Sirolimus, “Sir”; red bar: anti-CD154, 
“5C8”; blue bar: Belatacept, “Bela”).
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Figure 4. 
CMV-specific T lymphocyte responses as measured by IFN-γ ELISPOT: Responses to 
whole peptide (WP) pools of rhesus CMV IE1 (Black), IE2 (Blue), pp65 (Green), and IL-10 
(Orange) and rhesus CMV Sonicate (Yellow) are shown as spot-forming cells (SFC) per 
1×106 lymphocytes. Results for four evaluable transplant recipients (R.51, R.53, R55, R.58), 
and their corresponding donors are shown. The threshold for a positive signal with this assay 
is 50 SFC/1×106 lymphocytes (indicated with the dashed line).
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Figure 5. 
Longitudinal analysis of hematologic reconstitution after transplant. Shown are the white 
blood cell count (WBC = black circles), absolute neutrophil count (ANC = blue squares), 
and absolute lymphocyte count (ALC = red triangles). Color-coded bars below each graph 
indicate duration of immunosuppression (black bar: Sirolimus, “Sir”; red bar: anti-CD154, 
“5C8”; blue bar: Belatacept, “Bela”). Normal values are shown in the graph (mean +/− 
SEM) for WBC (gray bar), ANC (red bar), ALC (blue bar).
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Figure 6. Immunophenotypic analysis of T cell subset balance after transplant in R.51
(A) Longitudinal analysis of R.51 showing the absolute number of CD3+/CD20− T cells, 
CD3−/CD20+ B cells, CD3+/CD20−/CD4+/CD8− T cells and CD3+/CD20−/CD4−/CD8+ 
T cells in R.51. Black circles: CD3+T cells. Pink upside triangles: CD20+ B cells. Red 
squares: CD4+ T cells. Blue triangles: CD8+ T cells. X-axis: Day post-transplant. Y-axis: 
Absolute cell counts. Color-coded bars below each graph indicate duration of 
immunosuppression (black bar: Sirolimus, “Sir”; red bar: anti-CD154, “5C8”; blue bar: 
Belatacept, “Bela”).
(B) Longitudinal analysis of R.51 showing absolute numbers and relative % of either CD4+ 
or CD8+ T cell subsets, defined as follows: Naive (CD28+/CD95−, blue circles), Central 
memory (CD28+/CD95+, red squares) and Effector memory (CD28−/CD95+, black 
triangles). X-axis: Day post-transplant. Y-axis: Absolute cell counts or % of CD4+ or CD8+ 
T cells. Color-coded bars below each graph indicate duration of immunosuppression (black 
bar: Sirolimus, “Sir”; red bar: anti-CD154, “5C8”; blue bar: Belatacept, “Bela”).
(C) Longitudinal analysis of R.51 showing absolute numbers and % of CD4+ T cells of 
CD4+/CD3+/FoxP3+/CD25+ Tregs. X- axis: Days post-transplant. Y-axis: absolute cell 
count or % Tregs of total CD4+ T cells. Color-coded bars below each graph indicate 
duration of immunosuppression (black bar: Sirolimus, “Sir”; red bar: anti-CD154, “5C8”; 
blue bar: Belatacept, “Bela”).
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Figure 7. Skin grafting in long-term surviving transplant recipients, showing autologous skin 
grafts, donor skin grafts, and non-recipient, non-donor “third party” skin grafts
(A) R.51: Representative photographs of autologous, donor and third-party skin grafts at 
Days 0, 9, 34, 69 and 104 after graft placement. To the right of each graft, representative 
hemotoxylin and eosin (H&E) staining is shown documenting lymphocyte infiltration of the 
third party graft without infiltration of either the autologous or donor skin grafts.
(B) R.52: Representative photographs of autologous, donor and third-party skin grafts at 
Days 0, 9, 34, 69 and 86 after graft placement. Right column: Representative H&E staining 
of the autologous graft showing no lymphocytic infiltration, representative H&E staining of 
the donor graft showing lymphocytic infiltration and representative H&E staining of the 
third-party allograft with eschar formation post-rejection.
(C) R.53: Representative photographs of autologous, donor and third-party skin grafts at 
Days 0, 9, 20, 46, and 51 after graft placement. Right column: Representative H&E staining 
of the autologous graft showing no lymphocytic infiltration, representative H&E staining of 
the donor graft showing lymphocytic infiltration and representative H&E staining of the 
third-party allograft with eschar formation post-rejection.
(D) Graph showing the relationship between the % T cell chimerism (Y-axis) and donor skin 
graft acceptance (x axis). Data is from R.51, R.52 and R.53 from the current study and for a 
previously reported (36) recipient (‘RQq9’).
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